About company
NIR is a biopharmaceutical company developing a suite of small-molecule antagonists targeting inappropriate inflammatory responses of the innate immune system via the NLRP3 pathway, which is believed to underlie a variety of serious diseases. The Company is developing chemically distinct systemic, gut-directed and CNS-penetrant drug candidates to address a breadth of indications triggered by NLRP3, including metabolic, fibrotic, autoimmune, autoinflammatory, and neurodegenerative diseases. IFM Tre was founded in 2017 and headquartered in Boston, Massachusetts.
- US 855 boylston street
- info@ifmthera.com
- Unknown
- ifmthera.com
- Not verified company
